From GlobeNewswire:

G1 Therapeutics announced that CEO Jack Bailey will provide a corporate presentation during the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024, at 1:30 PM PST. The webcast will be accessible on the company’s Events & Presentations page at http://www.g1therapeutics.com. G1 Therapeutics, Inc. aims to develop and deliver next-generation therapies to improve the lives of those affected by cancer. The company’s first commercial product is COSELA® (trilaciclib). G1’s goal is to provide innovative therapeutic advances for people living with cancer. G1 Therapeutics® and COSELA® are trademarks of G1 Therapeutics, Inc. Contacts: Will Roberts, Communications Officer, Vice President, Investor Relations, and Corporate Communications at (919) 907-1944 or [email protected]. Follow them on Twitter @G1Therapeutics and on LinkedIn.



Read more: G1 Therapeutics to Participate in the 42nd Annual J.P.